Acutus Medical shares are trading higher after the company was granted European patent number EP3043701 titled "Devices And Methods For Determination Of Electrical Dipole Densities On A Cardiac Surface (And Methods For Diagnosing Tissue Health)."
Portfolio Pulse from Benzinga Newsdesk
Acutus Medical's stock is trading higher following the grant of European patent EP3043701, which covers devices and methods for determining electrical dipole densities on cardiac surfaces, a technology that can be used for diagnosing tissue health.
January 25, 2024 | 3:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Acutus Medical, Inc. (AFIB) has been granted a European patent for its cardiac diagnostic technology, potentially strengthening its market position and product offering in Europe.
The grant of a new patent typically provides a company with a competitive edge by protecting its intellectual property, potentially leading to increased market share and revenue in the protected region. For Acutus Medical, this European patent could enhance its product portfolio's appeal and lead to increased sales in Europe, which is likely to have a positive impact on the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 90